GIST | Clinical

Pimitespib Shows Significant PFS Improvement in Advanced Refractory GIST

June 08, 2021

Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.

Increased Dose of Ripretinib Improves Survival in Heavily Pretreated Advanced GIST

June 04, 2021

Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.

More Benefit Observed With Avapritinib Than Other TKIs in Mutated GIST

May 21, 2021

A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation